Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee survey.


Journal

ESMO open
ISSN: 2059-7029
Titre abrégé: ESMO Open
Pays: England
ID NLM: 101690685

Informations de publication

Date de publication:
04 2023
Historique:
received: 10 10 2022
revised: 04 01 2023
accepted: 04 01 2023
medline: 25 4 2023
pubmed: 27 2 2023
entrez: 26 2 2023
Statut: ppublish

Résumé

Following a European Society for Medical Oncology Women for Oncology (ESMO W4O) survey in 2016 showing severe under-representation of female oncologists in leadership roles, ESMO launched a series of initiatives to address obstacles to gender equity. A follow-up survey in October 2021 investigated progress achieved. The W4O questionnaire 2021 expanded on the 2016 survey, with additional questions on the impact of ethnicity, sexual orientation and religion on career development. Results were analysed according to respondent gender and age. The survey sample was larger than in 2016 (n = 1473 versus 482), especially among men. Significantly fewer respondents had managerial or leadership roles than in 2016 (31.8% versus 51.7%). Lack of leadership development for women and unconscious bias were considered more important in 2021 than in 2016. In 2021, more people reported harassment in the workplace than in 2016 (50.3% versus 41.0%). In 2021, ethnicity, sexual orientation and religion were considered to have little or no impact on professional career opportunities, salary setting or related potential pay gap. However, gender had a significant or major impact on career development (25.5% of respondents), especially in respondents ≤40 years of age and women. As in 2016, highest ranked initiatives to foster workplace equity were promotion of work-life balance, development and leadership training and flexible working. Significantly more 2021 respondents (mainly women) supported the need for culture and gender equity education at work than in 2016. Gender remains a major barrier to career progression in oncology and, although some obstacles may have been reduced since 2016, we are a long way from closing the gender gap. Increased reporting of discrimination and inappropriate behaviour in the workplace is a major, priority concern. The W4O 2021 survey findings provide new evidence and highlight the areas for future ESMO interventions to support equity and diversity in oncology career development.

Sections du résumé

BACKGROUND
Following a European Society for Medical Oncology Women for Oncology (ESMO W4O) survey in 2016 showing severe under-representation of female oncologists in leadership roles, ESMO launched a series of initiatives to address obstacles to gender equity. A follow-up survey in October 2021 investigated progress achieved.
MATERIALS AND METHODS
The W4O questionnaire 2021 expanded on the 2016 survey, with additional questions on the impact of ethnicity, sexual orientation and religion on career development. Results were analysed according to respondent gender and age.
RESULTS
The survey sample was larger than in 2016 (n = 1473 versus 482), especially among men. Significantly fewer respondents had managerial or leadership roles than in 2016 (31.8% versus 51.7%). Lack of leadership development for women and unconscious bias were considered more important in 2021 than in 2016. In 2021, more people reported harassment in the workplace than in 2016 (50.3% versus 41.0%). In 2021, ethnicity, sexual orientation and religion were considered to have little or no impact on professional career opportunities, salary setting or related potential pay gap. However, gender had a significant or major impact on career development (25.5% of respondents), especially in respondents ≤40 years of age and women. As in 2016, highest ranked initiatives to foster workplace equity were promotion of work-life balance, development and leadership training and flexible working. Significantly more 2021 respondents (mainly women) supported the need for culture and gender equity education at work than in 2016.
CONCLUSIONS
Gender remains a major barrier to career progression in oncology and, although some obstacles may have been reduced since 2016, we are a long way from closing the gender gap. Increased reporting of discrimination and inappropriate behaviour in the workplace is a major, priority concern. The W4O 2021 survey findings provide new evidence and highlight the areas for future ESMO interventions to support equity and diversity in oncology career development.

Identifiants

pubmed: 36842299
pii: S2059-7029(23)00001-7
doi: 10.1016/j.esmoop.2023.100781
pmc: PMC10163010
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

100781

Informations de copyright

Copyright © 2023 European Society for Medical Oncology (ESMO). Published by Elsevier Ltd.. All rights reserved.

Références

Lancet. 2019 Feb 9;393(10171):560-569
pubmed: 30739691
Lancet Gastroenterol Hepatol. 2019 Dec;4(12):893
pubmed: 31696819
ESMO Open. 2018 Sep 21;3(6):e000422
pubmed: 30273420
ESMO Open. 2018 Sep 21;3(6):e000423
pubmed: 30273418
ESMO Open. 2021 Dec;6(6):100281
pubmed: 34924143
Ann Oncol. 2014 Feb;25(2):525-8
pubmed: 24425791
BMJ. 2019 Mar 5;364:l987
pubmed: 30837216
ESMO Open. 2020 Apr;5(2):
pubmed: 32354723
JAMA Netw Open. 2020 Mar 2;3(3):e200708
pubmed: 32159809
Lancet. 2019 Feb 9;393(10171):499-502
pubmed: 30739670
Adv Radiat Oncol. 2018 Oct 21;3(4):478-483
pubmed: 30370345
CMAJ. 2021 Feb 16;193(7):E244-E250
pubmed: 33593950

Auteurs

H Linardou (H)

4th Oncology Department & Comprehensive Clinical Trials Centre, Metropolitan Hospital, Athens, Greece. Electronic address: elinardou@otenet.gr.

A A Adjei (AA)

Mayo Clinic, Rochester, USA.

J Bajpai (J)

Tata Memorial Centre, Homi-bhabha National Institute, Mumbai, India.

S Banerjee (S)

The Royal Marsden NHS Foundation Trust, Institute of Cancer Research, London, UK.

A S Berghoff (AS)

Division of Oncology, Department of Medicine 1, Medical University of Vienna, Vienna, Austria.

C Cerqueira Mathias (CC)

Grupo Oncoclinicas and Hospital Santa Izabel, Bahia, Brazil.

S P Choo (SP)

Curie Oncology Singapore, National Cancer Centre Singapore.

R Dent (R)

National Cancer Center Singapore, Duke-NUS Medical School, Singapore.

E Felip (E)

Medical Oncology Department, Vall d'Hebron University Hospital, Thoracic Oncology and H&N Cancer Unit, Vall d'Hebron Institute of Oncology (VHIO), UVic-UCC, Barcelona, Spain.

A J S Furness (AJS)

Royal Marsden NHS Foundation Trust, London, UK.

M C Garassino (MC)

University of Chicago Medicine & Biological Sciences, Section of Hematology/Oncology, Chicago, USA.

E Garralda (E)

Early Drug Development Unit, VHIO-Vall d'Hebron Institute of Oncology, HUVH-Vall d'Hebron University Hospital, Barcelona, Spain.

A Konsoulova-Kirova (A)

National Oncology Hospital, Sofia, Bulgaria.

A Letsch (A)

Department of Medicine II, Hematology and Oncology, University Hospital Schleswig-Holstein, Kiel, Germany.

A M Menzies (AM)

Melanoma Institute Australia, The University of Sydney, Sydney, Australia.

D Mukherji (D)

Clemenceau Medical Center Dubai, Dubai, United Arab Emirates.

S Peters (S)

Oncology Department-CHUV, Lausanne University, Lausanne.

C Sessa (C)

Ente Ospedaliero Cantonale, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.

J Tsang (J)

Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China.

J C-H Yang (JC)

Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.

P Garrido (P)

Universidad de Alcalá, Medical Oncology Department, IRYCIS, Hospital Universitario Ramón y Cajal, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH